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Atypical antipsychotics such as clozapine and olanzapine have been shown to enhance
histamine turnover and this effect has been hypothesized to contribute to their improved
therapeutic proﬁle compared to typical antipsychotics. In the present study, we examined
the effects of antipsychotic drugs on histamine (HA) efﬂux in the mPFC of the rat by means
of in vivo microdialysis and sought to differentiate the receptor mechanisms which under-
lie such effects. Olanzapine and clozapine increased mPFC HA efﬂux in a dose related
manner. Increased HA efﬂux was also observed after quetiapine, chlorpromazine, and per-
phenazine treatment. We found no effect of the selective 5-HT2A antagonist MDL100907,
5-HT2c antagonist SB242084, or the 5-HT6 antagonist Ro 04-6790 on mPFC HA efﬂux.
HA efﬂux was increased following treatment with selective H1 receptor antagonists pyril-
amine, diphenhydramine, and triprolidine, the H3 receptor antagonist ciproxifan and the
mixed 5-HT2A/H1 receptor antagonist ketanserin. The potential novel antipsychotic drug
FMPD, which has a lower afﬁnity at H1 receptors than olanzapine, did not affect HA efﬂux.
Similarly, other antipsychotics with lower H1 receptor afﬁnity (risperidone, aripiprazole, and
haloperidol) were also without effect on HA efﬂux. Finally, HA efﬂux after antipsychotic
treatment was signiﬁcantly correlated with afﬁnity at H1 receptors whereas nine other
receptors, including 5-HT2A, were not. These results demonstrate that both typical and
atypical antipsychotics increase mPFC histamine efﬂux and this effect may be mediated
via antagonism of histamine H1 receptors.
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INTRODUCTION
Although the introduction of typical antipsychotic drugs in the
1950s revolutionized the treatment of schizophrenia, their use has
been impeded by a number of side effects such as extrapyramidal
symptoms (EPS), tardive dyskinesia, and their failure to adequately
treat the negative and cognitive symptoms in schizophrenia. Atyp-
ical antipsychotics such as clozapine, olanzapine, risperidone,
ziprasidone, and aripiprazole differ from typical antipsychotic
drugs in that they have a reduced liability for EPS and generally do
not induce sustained increases in serum prolactin. Some atypical
antipsychotics drugs also appear to improve not only the posi-
tive symptoms, but may be of beneﬁt in the treatment of negative
and cognitive deﬁcits when compared to the typical antipsychotics
(Meltzer and Okayli, 1995; Meltzer and McGurk, 1999; Keefe et al.,
2007).
Despite much research, the mechanisms responsible for the
improved therapeutic proﬁle of atypical antipsychotics drugs com-
pared to typical antipsychotics are not fully understood and the
task of unveiling such mechanisms is complicated by the complex
receptor pharmacology of antipsychotic drugs. Indeed, typical and
atypical antipsychotics differ greatly in terms of their ability to
interact with a number of dopaminergic (e.g., D2, D3, and D4;
Seeman and Lee, 1975; Seeman et al., 1997) serotonergic (e.g.,
5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7; Roth et al., 1994;
Bymaster et al., 1996), adrenergic/muscarinic acetylcholine (Zeng
et al., 1997), and histaminergic receptors [e.g., H1 (Peroutka et al.,
1980), H2 and H3 (Bymaster et al., 1999; Lovenberg et al., 2000)].
Nevertheless previous preclinical studies have shown that atypical
antipsychotic drugs but not typical antipsychotic drugs such as
haloperidol or chlorpromazine, preferentially enhance dopamine
(DA), norepinephrine, and acetylcholine efﬂux in the rat medial
prefrontal cortex (mPFC) and hippocampus compared with the
nucleus accumbens (Li et al., 1998; Kuroki et al., 1999; Zhang et
al., 2000; Assié et al., 2005). These effects have been hypothesized
to contribute to the enhanced ability of atypical antipsychotic
drugs to improve cognitive function and negative symptoms in
patients with schizophrenia (Morisset et al., 1999; Huang et al.,
2008).
The monoamine histamine is known to function as a neuro-
transmitter, with neurons originating from the posterior hypo-
thalamus tuberomammillary nucleus (PH-TMN) and projecting
to regions that include the cortex, hippocampus, amygdala, and
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striatum. In the brain, histamine exerts it effects through three
G-protein coupled receptors: H1, H2, and H3 and is involved
in the regulation of many physiological functions including, the
sleep–wake cycle, feeding, arousal, emotion, memory, and cogni-
tion (Schwartz et al., 1991; Haas and Panula, 2003; Haas et al.,
2008). Despite the role of histamine in many centrally mediated
processes relevant to schizophrenia, the effect that antipsychotic
drug treatment has on histaminergic neurotransmission has not
been extensively studied. One earlier study by Morisset et al.
(1999) did however reveal that atypical antipsychotics enhance
tissue levels of the histamine metabolite tele-methylhistamine
(t-MeHA) in the mPFC and striatum of mice. This effect was
comparable to that of the potent H3 receptor antagonist ciprox-
ifan and appeared to be selective for atypical antipsychotics
drugs as enhanced t-MeHA was not observed after treatment
with typical antipsychotics. The mechanism(s) by which atypi-
cal antipsychotic drugs modulate histaminergic neurotransmis-
sion are unclear but Morisset et al. (1999) hypothesized that
it may be related to their greater ability to antagonize 5-HT2A
receptors compared to typical antipsychotics (Morisset et al.,
1999). These results did provide evidence that atypical antipsy-
chotic drugs can enhance histaminergic activity in limbic brain
regions and raised the possibility that in addition to their effects
of DA, NE, and Ach, enhanced histaminergic neurotransmis-
sion may also contribute to the improved efﬁcacy of atypical
antipsychotics.
In the present study, we sought to examine the effects of atyp-
ical (olanzapine, clozapine, risperidone, quetiapine, and aripipra-
zole) and typical (chlorpromazine, perphenazine, and haloperi-
dol) antipsychotic drugs on histamine efﬂux in the mPFC of the
rat by means of in vivo microdialysis. In order to differentiate
the receptor mechanism(s) underlying the ability of antipsy-
chotic drugs to modulate histaminergic activity, we also exam-
ined the histamine response in the mPFC to ligands selective for
monoaminergic receptors (H1, H3, 5-HT2A, 5-HT2C, 5-HT6) that
are targeted by antipsychotic drugs. In addition, we attempted to
correlate the changes in mPFC histamine efﬂux for the antipsy-
chotic drugs studied with their binding afﬁnities at 11 monoamin-
ergic receptors using binding afﬁnities previously determined by
the NIMH Psychoactive Drug Screening Program (Roth et al.,
2004).
MATERIALS AND METHODS
ANIMALS
All experiments were conducted in accordance with the National
Institutes of Health Guide for Care and Use of Laboratory Ani-
mals (http://www.nap.edu/readingroom/books/labrats) and were
approved by the Eli Lilly Institutional Animal Care and Use Com-
mittee. Subjects were male Sprague-Dawley rats (Taconic Ger-
mantown, NY, USA) weighing between 250 and 350 g. Rats were
singly housed with standard laboratory chow and water available
ad libitum and maintained on a 12-h light/dark cycle (lights on
at 06:00, lights off at 18:00). All efforts were made to minimize
the discomfort and the number of animals used. All experiments
were performed between 8 am and 4 pm using appropriate vehicle
controls.
MICRODIALYSIS PROCEDURES
Parts of this microdialysis technique have been previously
described (Perry et al., 2008; Fell et al., 2010). However for these
experiments all surgeries were carried out by Taconic (German-
town, NY, USA) 5–7 days before the experiment. In brief, the rats
were anesthetized with isoﬂurane gas and mounted in a stereo-
taxic frame. A microdialysis guide and stylet (BASi,West Lafayette,
IN, USA) were stereotaxically placed in the locations given below.
The stereotaxic coordinates for the medial prefrontal cortex (PFC)
cannula were: A (anterior to bregma), 3.2 mm; L (lateral from the
midsagittal suture) 0.8 mm; andV (ventral from the dura surface),
−2 mm. A concentric type probe (PFC=BR-4) from BASi (West
Lafayette, IN, USA) to match the implanted cannula with a 4 mm
(PFC) membrane tip extending below the cannula was ﬂushed
with water and carefully inserted through the cannula 16 h before
the experiment began. Immediately after insertion of the probe
the rat was placed in the cage where the experiment was to be
conducted in order to acclimate to the new cage overnight.
On the morning of the experiment the rat’s probe was con-
nected to a liquid swivel then to a fraction collection system
for freely moving animals [BioAnalytical Systems (BASi), West
Lafayette, IN, USA]. The input tube of the dialysis probe was
connected to a syringe pump (BASi) which delivered an arti-
ﬁcial cerebrospinal ﬂuid containing 150 mM NaCl, 3 mM KCl,
1.7 mM CaCl2, and 0.9 mM MgCl2 (pH 6.0) to the probe at a
rate of 1.5 μl/min. The output tubes from the rats were attached
to a refrigerated fraction collector (BASi). After a period of 2 h for
equilibration of the probe and establishment of stable monoamine
baseline levels, collection of 30 min fractions was started. The
ﬂow from the output lines was collected in 200 μl plastic tubes,
20 μl of which was injected onto the HPLC system for histamine
analysis. Three baseline samples were collected before injection of
any drugs. For the central administration of clozapine or pyril-
amine directly into the PFC, both compounds were delivered
via the microdialysis probe. After the establishment of a stable
baseline, the inlet tubing from a syringe containing aCSF was
manually switched to one containing the drug at the appropriate
concentration.
BIOCHEMICAL DETERMINATIONS
Histamine analysis
Histamine was analyzed using a modiﬁed version of the of the
method previously described by Westerink et al. (2002). Hist-
amine was separated on an HPLC column and quantiﬁed by
ﬂuorimetric detection after a postcolumn derivatization with an
o-phthaldialdehyde-containing reagent as follows. The mobile
phase consisted of 0.16 M KH2PO4, 0.1 mM sodium octane-
sulfonic acid, and 0.1 mM EDTA; the pH was adjusted to 4.6.
The ﬂow rate of the mobile phase was 0.7 ml/min. The eluent
line was connected by a T-piece for mixing with a reagent line
through which a 0.02% solution of o-phthaldialdehyde (97%
OPA, Sigma) in 0.15 M NaOH was delivered at 0.6 ml/min. The
OPA reagent was mixed with the eluent in a mixing coil of
Teﬂon tubing (OD 1.1 mm, ID 0.55 mm; length 1 m) to allow
the derivatization reaction to proceed at ambient temperature.
The OPA reagent solution was prepared fresh daily, protected
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from light, and kept cooled in ice. Histamine was separated on
a reverse-phase column, a BDS Hypersil, 3μm, C18 analytical
column (4.6× 100 mm from Thermo-Fisher). The ﬂuorescence
of the reaction product was measured by a ﬂuorimeter (Jasco
FP-920; excitation: 350 nm; emission: 450 nm) set at the high-
est sensitivity. The sensitivity for histamine was about 20 fmol per
sample (20 μl).
DRUGS
Olanzapine, ciproxifan, quetiapine, aripiprazole, ketanserin,
SB242048, R0-46 6790, and FMPD [6-Fluoro-10-[3-(2-methox
yethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H -3-thia-4,9-diaza-
benzo[f]azulene] were synthesized at Lilly Research Laborato-
ries (Indianapolis, IN, USA). MDL100907, clozapine, haloperidol,
pyrilamine, and diphenhydramine, were obtained from Sigma
Aldrich (St. Louis, MO, USA). Risperidone was purchased from
TorontoResearchChemicals Inc,NorthYork,Canada. Triprolidine
was purchased from Tocris. Clozapine, olanzapine, risperidone,
quetiapine, haloperidol, MDL100907, ciproxifan, and FMPD were
dissolved in a few drops of an 11.5% solution of lactic acid and
diluted in 0.9% saline. Pyrilamine, diphenhydramine, and tripro-
lidine were dissolved in sterile water. Unless stated otherwise, all
drugs were administered via the subcutaneous route (s.c.) in a
volume of 1 ml/kg. Ketanserin and aripiprazole suspended in a
solution consisting of 1% carboxymethylcellulose, 0.25% Tween
80, and 0.05% Dow antifoam and administered orally (p.o.) in a
volume of 2 ml/kg. SB242048 and Ro 04-6790 were suspended in
a solution consisting of 1% carboxymethylcellulose, 0.25% Tween
80, and 0.05% Dow antifoam and administered i.p. in a volume
of 2 ml/kg. For central administration clozapine was dissolved in
a few drops of an 11.5% solution of lactic acid and diluted aCSF
and the pH adjusted to 7.4 with the drop-wise addition of 5 N
NaOH. Pyrilamine was dissolved in aCSF and the pH adjusted to
7.4 with the drop-wise addition of 5 N NaOH. Both compounds
were delivered via the microdialysis probe by manually switching
the inlet tubing from a syringe containing aCSF to one containing
the drug.
The selection of doses for both typical and atypical antipsy-
chotic drugs tested was based on receptor occupancy data (Kapur
et al., 2003; Barth et al., 2006;Natesan et al., 2006). For example, the
ED50 (dose required to block 50%of raclopride binding) values for
olanzapine, clozapine, haloperidol, risperidone, quetiapine, chlor-
promazine, and aripiprazole in the rat brain are 0.57, 7.26, 0.02,
0.32, 11.8, 5.1, and 0.7 mg/kg respectively. In addition, the doses
of antipsychotic drugs tested for single point investigation have
previously been shown to be efﬁcacious in behavioral paradigms
including amphetamine induced locomotor activity and condi-
tioned avoidance responding. The doses of the potential novel
antipsychotic FMPDwere selectedon the basis of efﬁcacy inbehav-
ioral models as previously described by Rasmussen et al. (2005).
The doses of the receptor selective compounds were selected on
the basis of ex vivo and in vivo occupancy data for the respective
receptors. In the absence of binding data, data from other pharma-
cological and biochemical assays revealing activity at the respective
receptors were used to select relevant doses (Bentley et al., 1999;
Morisset et al., 1999; Goudie et al., 2004; Marek et al., 2005; Le
et al., 2008).
STATISTICAL ANALYSIS
All dialysis probe placements were checked by perfusing a tetra
red solution through the dialysis probe for subsequent histological
examination. Only results derived from rats with correctly posi-
tioned probes were included in the data analysis. All microdialysis
data were calculated as percent of baseline with 100% deﬁned as
the average of the three drug pre-injection values (n = 5–6 per
group). Time course data represent the percent change from base-
line and were analyzed by two-way analysis of variance (ANOVA)
followed by post hoc Bonferroni corrected t -test. Summary data
represent the average percent of baseline HA (±SEM) for the 3.5 h
post-drug or vehicle. Where there were more than two treatment
groups the data were subjected to one-way analysis of variance
(ANOVA) followed by a post hoc Dunnett’s corrected t -test. When
only two treatment groups were present the data were analyzed by
independent samples, two-tailed Student’s t -test. Ki values used
in our correlation analysis were determined by the NIMH Psy-
choactive Drug Screening Program (Roth et al., 2004). The Ki
values used in our analysis are listed as NIMH Psychoactive Drug
Screening Program assay certiﬁed data, determined from assays
using cloned human or rat receptors with drugs of interest as test
ligands. For Ki values for which PDSP certiﬁed assay data were
not listed, we used the average Ki value from assay data compiled
on the PDSP web site using cloned human and rat receptors with
drug of interest as the test ligand (Roth et al., 2004). Ki values from
cloned human and rat receptors for the potential novel antipsy-
chotic FMPD were identiﬁed from a previously published study
by Rasmussen et al. (2005). Ki values used in our analysis are
listed in Tables S1 and S2 in Supplementary Material. All bind-
ing data analyzed in our study have been previously reported by
other investigators. Percent mPFC histamine efﬂux and binding
afﬁnities (Ki) were log-transformed before analysis. All analyses
were performed using the GraphPad PRISM statistical program
(GraphPad, San Diego, CA, USA) and the level of signiﬁcance was
set at P < 0.05.
RESULTS
BASAL CONCENTRATIONS OF HISTAMINE IN MICRODIALYZATES FROM
THE MEDIAL PREFRONTAL CORTEX OF THE RAT
Under the present experimental conditions, average pre-injection,
basal histamine concentrations in the mPFC were 4.13± 0.02 nM
(based a total of 192 rats used in experiments presented in
Figures 1–4; Tables 1 and 2).
EFFECTS OF THE ATYPICAL ANTIPSYCHOTIC DRUGS ON HISTAMINE
EFFLUX IN THE mPFC
The atypical antipsychotic drugs clozapine (Figures 1A,B) and
olanzapine (Figures 1C,D) signiﬁcantly increased extracellular
histamine in the mPFC. A two-way ANOVA revealed signiﬁ-
cant effects of drug, time, and interaction after clozapine treat-
ment: drug [F(3, 160)= 46.1; P < 0.001], time [F(9, 160)= 7.97;
P < 0.001], and drug× time [F(27, 160)= 3.27; P < 0.001] and
olanzapine treatment: drug [F(3, 190)= 40.29; P < 0.001], time
[F(9, 190)= 3.84;P < 0.001], and drug× time [F(27, 190)= 2.67;
P < 0.001]. Post hoc analysis showed signiﬁcant increases in HA
efﬂux after clozapine and olanzapine treatment as compared to
the vehicle treated group. Analysis of the average percent of
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FIGURE 1 | Effect of the atypical antipsychotic drug (A,B) clozapine
(1–10mg/kg, s.c.) or (C,D) olanzapine (1–10mg/kg, s.c.) on histamine
efflux in the mPFC. Data are mean±SEM of the dialyzate HA levels,
expressed as a percentage of the baseline. Time course data shown in (A)
and (C) were analyzed by two-way analysis of variance (ANOVA) followed by
post hoc Bonferroni corrected t -test. Summary data (B) and (D) represent
average percent of baseline HA (±SEM) for the 3.5 h post-drug or vehicle and
were subjected to one-way analysis of variance (ANOVA) followed by post hoc
Dunnett’s corrected t -test (n =5–6 per group). **P <0.01 compared to the
vehicle treated animals.
baseline over the 3.5 h post-injection of clozapine (Figure 1B) or
(Figure 1D) olanzapine revealed a signiﬁcant effect of treatment
on histamine efﬂux between groups: clozapine [F(3, 19)= 14.3;
P < 0.001]; olanzapine [F(3, 21)= 7.02; P < 0.01]. Post hoc analy-
sis showed that clozapine at 3 mg/kg (P < 0.01) and 10 mg/kg
(P < 0.01) and olanzapine at 3 mg/kg (P < 0.01) and 10 mg/kg
(P < 0.01) signiﬁcantly increase histamine efﬂux compared to the
vehicle treated group. The increases in mPFC histamine seen after
both clozapine and olanzapine at 1 mg/kg were not statistically
signiﬁcant. After treatment with quetiapine (20 mg/kg; s.c.) a two-
wayANOVA revealed a signiﬁcant effect of drug [F(1, 90)= 14.02;
P < 0.001] but no time or drug × time interaction. Following
risperidone (1 mg/kg; s.c.) both drug [F(1, 70)= 4.747; P < 0.05]
and time [F(9, 70)= 4.207; P < 0.001] were signiﬁcant but the
interaction between drug × time was not. Aripiprazole (10 mg/kg,
p.o.) treatment did not signiﬁcantly affect HA efﬂux compared
to the vehicle treated group. Analysis of the average percent of
baseline over the 3.5 h post-injection of quetiapine, revealed that
only quetiapine (20 mg/kg) signiﬁcantly increased HA efﬂux in
the mPFC compared to the vehicle treated group [t (9)= 2.819;
P < 0.05]. Risperidone (1 mg/kg) induced a slight increase in
HA release, however, this failed to reach statistical signiﬁcance
[t (8)= 1.162; NS]. Aripiprazole was without effect on HA release
when compared to the vehicle treated group [t (9)= 0.066; NS].
EFFECT OF TYPICAL ANTIPSYCHOTIC DRUGS ON HISTAMINE EFFLUX IN
THE mPFC
Of the typical antipsychotic drugs tested, Chlorpromazine
(10 mg/kg) and perphenazine (3 mg/kg) were found to signiﬁ-
cantly elevate HA efﬂux in the mPFC (see Table 1). A two-way
ANOVA revealed signiﬁcant effect of drug and a signiﬁcant inter-
action between drug and time after chlorpromazine treatment:
drug [F(1, 90)= 79.27;P < 0.001], time [F(9, 90)= 1.15;NS], and
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FIGURE 2 | Effects of the selective 5-HT2A receptor antagonist MDL100907
(0.125 and 0.25mg/kg, s.c.) or vehicle on histamine efflux in the mPFC.
Data are mean±SEM of the dialyzate HA levels, expressed as a percentage
of the baseline. Time course data shown in (A) were analyzed by two-way
analysis of variance (ANOVA) followed by post hoc Bonferroni corrected t -test.
Summary data (B) represent average percent of baseline HA (±SEM) for the
3.5 h post-drug or vehicle and were subjected to one-way analysis of variance
(ANOVA) followed by post hoc Dunnett’s corrected t -test (n =5–6 per group).
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FIGURE 3 | Effects of the selective H1 receptor antagonist pyrilamine
(1–20mg/kg, s.c.) or vehicle on histamine efflux in the mPFC. Data
are mean±SEM of the dialyzate HA levels, expressed as a percentage
of the baseline. Time course data shown in (A) were analyzed by
two-way analysis of variance (ANOVA) followed by post hoc Bonferroni
corrected t -test. Summary data (B) represent average percent of
baseline HA (±SEM) for the 3.5 h post-drug or vehicle and were
subjected to one-way analysis of variance (ANOVA) followed by post hoc
Dunnett’s corrected t -test (n =4–6 per group). **P <0.01 compared to
the vehicle treated animals.
drug× time [F(9, 90)= 4.66; P < 0.001] and perphenazine treat-
ment: drug [F(1, 80= 58.47; P < 0.001], time [F(9, 80)= 1.94;
NS], and drug× time [F(9, 80)= 3.33; P < 0.01]. A two-way
ANOVA after haloperidol treatment did not reveal a signiﬁcant
difference between groups. Post hoc analysis showed signiﬁcant
increases in HA efﬂux after chlorpromazine and perphenazine
treatment as compared to the vehicle treated group.Analysis of the
average percent of baseline over the 3.5 h post-injection of drug
revealed signiﬁcant increases in HA efﬂux compared to the vehicle
treated group after treatment with chlorpromazine [t (9)= 4.83;
P < 0.001] and perphenazine [t (8)= 4.195; P < 0.01] but not
haloperidol t (7)= 0.204; NS].
EFFECTS OF RECEPTOR SUBTYPE SELECTIVE ANTAGONISTS ON
EXTRACELLULAR HISTAMINE IN THE RAT mPFC
Since most atypical antipsychotic drugs have actions at several
receptor, to further explore the underlying mechanism of action
of drug induced histamine efﬂux,we examined the effects of selec-
tive compounds for various receptors (see Table 2). Signiﬁcant
increases in HA efﬂux were observed after the administration
of the histamine H3 receptor antagonist ciproxifan (1 mg/kg,
s.c.): drug [F(1, 90)= 84.35; P < 0.001], time [F(9, 90)= 2.09;
P < 0.05], and drug× time [F(9, 90)= 4.57; P < 0.001] and the
mixed 5-HT2A/H1 receptor antagonist ketanserin: drug [F(2,
120)= 10.01; P < 0.001], time [F(9, 120)= 13.28; P < 0.001]
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FIGURE 4 |The effects of the potential novel antipsychotic drug FMPD
[6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H -3-
thia-4,9-diaza-benzo[f ]azulene] (1–10mg/kg) on histamine efflux in the
mPFC. Data are mean±SEM of the dialyzate HA levels, expressed as a
percentage of the baseline. Time course data shown in (A) FMPD were
analyzed by two-way analysis of variance (ANOVA) followed by post hoc
Bonferroni corrected t -test. Summary data (B) represent average percent of
baseline HA (±SEM) for the 3.5 h post-drug or vehicle and were subjected to
one-way analysis of variance (ANOVA) followed by post hoc Dunnett’s
corrected t -test (n =6 per group).
Table 1 |The effect of typical and atypical antipsychotics on histamine efflux in the mPFC.
Drug Dose (mg/kg) Route of administration HA baseline (nM) HA% of baseline (3.5 h average) P -value
Vehicle – s.c. 3.02±0.20 75.11±15.6
Chlorpromazine 10 s.c. 3.57±0.13 162.5±12.5 **
Perphenazine 3 s.c. 3.77±0.13 173.6±19.79 **
Haloperidol 0.5 s.c. 5.03±0.32 68.53±8.4 n.s.
Olanzapine 1 s.c. 3.50±0.19 103.2±12.3 n.s.
3 s.c. 4.20±0.43 163.2±14.7 **
10 s.c. 4.94±0.52 236.5±45.9 **
Clozapine 1 s.c. 5.53±0.79 114.8±16.4 n.s.
3 s.c. 4.13±0.40 172.8±19.1 **
10 s.c. 5.14±0.29 198.3±9.1 **
Quetiapine 20 s.c. 5.68±0.27 115.7±8.2 *
Risperidone 1 s.c. 6.92±0.86 92.1±10.1 n.s.
FMPD 1 s.c. 4.68±0.23 78.9±4.2 n.s.
5 s.c. 3.48±0.16 72.4±4.9 n.s.
10 s.c. 5.46±0.40 94.8±9.2 n.s.
Vehicle – p.o. 3.00±0.24 77.1±6.5
Aripiprazole 10 p.o. 3.79±0.14 70.4±7.6 n.s.
*P<0.05, **P<0.01 compared to the vehicle treated animals.
and there was a drug× time interaction [F(18, 80)= 13.76;
P < 0.05]. Post hoc analysis revealed signiﬁcant increases in HA
efﬂux after ciproxifan (0.5–3.5 h; P < 0.05–0.001) and ketanserin
4 (0.5 h; P < 0.05) and 8 mg/kg treatment (2.5–3.0 h; P < 0.05)
as compared to the vehicle treated group. Subsequent analysis
of average percent of baseline over 3.5 h post-injection of drug
revealed that ciproxifan [t (9)= 4.88; P < 0.001] and ketanserin
[F(2, 15)= 4.87; P < 0.05) at 8 mg/kg (P < 0.05) but not 4 mg/kg
increased mPFC histamine efﬂux (see Table 2). The effect of the
selective 5-HT2A receptor antagonist MDL 100907 on HA efﬂux
in the mPFC is shown in Figure 3. A two-way ANOVA revealed
an overall effect of drug [F(2, 120)= 3.81; P < 0.05] and time
[F(9, 120)= 16.7; P < 0.001] but no drug× time effect [F(18,
120) 1.61; P > 0.05]. Subsequent Bonferroni post hoc compar-
isons and analysis of the 3.5 h average data however did not
reveal any signiﬁcant alterations in histamine efﬂux in the mPFC
by MDL100907 at either 0.125 or 0.25 mg/kg [F(2, 15)= 1.54;
P > 0.05]. Additionally we also investigated the effects of the
selective 5-HT6 receptor antagonist Ro 04-6790 10 mg/kg and the
5-HT2c antagonist SB242048 10 mg/kg on HA efﬂux in the mPFC.
Two-way ANOVA indicated a signiﬁcant effect of drug following
the treatment with Ro 04-6790 [F(1, 81)= 4.57; P < 0.05] but
not SB242048 [F(1, 81)= 2.13; NS]. However, subsequent Bon-
ferroni post hoc comparisons and analysis of the average percent
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Table 2 |The effect of receptor subtype selective drugs on histamine efflux in the mPFC.
Drug Dose (mg/kg) Route of administration Receptor target HA baseline (nM) HA% of baseline (3.5 h average) P -value
Vehicle – s.c. – 3.02±0.20 75.11±15.6 –
Ciproxifan 1 s.c. H3 15.29±0.54 200.7±20.9 **
Diphenhydramine 20 s.c. H1 2.49±0.19 285.1±13.8 **
Triprolidine 35 s.c. H1 2.85±0.12 252.6±33.4 **
Pyrilamine 1 s.c. H1 2.96±0.18 99.24±10.19 n.s.
3 s.c. H1 1.86±0.10 127.9±11.3 n.s.
10 s.c. H1 3.07±0.18 170.8±14.8 **
20 s.c. H1 3.54±0.11 190.7±16.8 **
Vehicle – s.c. – 6.78±1.0 89.2±10.7 –
MDL100907 0.125 s.c. 5-HT2A 4.07±0.47 78.1±11.6 n.s.
0.25 s.c. 5-HT2A 1.67±0.15 103.0±7.7 n.s.
Vehicle – p.o. – 3.00±0.24 77.1±6.5 –
Ketanserin 4 p.o. 5-HT2A/H1 2.07±0.11 93.8±7.9 n.s.
8 p.o. 5-HT2A/H1 5.45±0.55 124.6±16.8 *
Vehicle – i.p. – 1.56±0.09 90.5±8.0 –
SB242048 10 i.p. 5-HT2C 3.09±0.24 104.2±12.6 n.s.
Ro 04-6790 10 i.p. 5-HT6 2.95±0.23 106.3±4.2 n.s.
*P<0.05, **P<0.01 compared to the vehicle treated animals.
of baseline over 3.5 h post-injection of drug did not reveal a signif-
icant increase in HA efﬂux compared to the vehicle control treated
group after either Ro 04-6790 [t (10)= 1.294; NS] or SB242048
[t (10)= 0.6919; NS].
As themixed5-HT2A/H1 receptor antagonist ketanserinbutnot
the selective 5-HT2A receptor antagonist MDL100907 increased
mPFC HA efﬂux we decided to evaluate the effects of selective
histamine H1 receptor antagonists on HA efﬂux in the mPFC.
As is shown in Figures 4A,B the selective H1 receptor antag-
onist pyrilamine markedly increased HA efﬂux in the mPFC.
A two-way ANOVA revealed a signiﬁcant effect of drug [F(4,
220)= 25.31; P < 0.001], time [F(9, 220)= 24.96; P < 0.001],
and a drug× time interaction [F(36, 220)= 3.754; P < 0.001].
Subsequent post hoc comparisons revealed signiﬁcant increases
in HA efﬂux after pyrilamine. Analysis of the average percent of
baseline over 3.5 h post-injection of drug revealed that pyrilamine
signiﬁcantly increased HA efﬂux in the mPFC [F(4, 26)= 11.8;
P < 0.001] at 10 mg/kg (P < 0.01) and 20 mg/kg (P < 0.01) but
not 1 or 3 mg/kg. Increases in mPFC HA efﬂux was also
observed after the administration of two other H1 receptor antag-
onists triprolidine: drug [F(1, 90)= 73.11; P < 0.001], time [F(9,
90)= 3.58; P < 0.001], drug× time [F(9, 90)= 4.19; P < 0.001]
and diphenhydramine: drug [F(1, 90)= 168.2; P < 0.001], time
[F(9, 90]= 7.38; P < 0.001], drug× time [F(9, 90)= 12.49;
P < 0.001]. Subsequent analysis of average percent of base-
line over 3.5 h post-injection of drug revealed that triproli-
dine [t (9)= 3.984; P < 0.01] and diphenhydramine [t (9)= 7.03;
P < 0.001] increased mPFC histamine efﬂux by ∼132.6 and
∼185.1% respectively (see Table 2).
EFFECT OF THE PUTATIVE ANTIPSYCHOTIC DRUG FMPD ON HISTAMINE
EFFLUX IN THE mPFC
As our earlier ﬁndings revealed that selective histamine H1
receptor antagonists such as pyrilamine, triprolidine, and
diphenhydramine increased histamine release in the mPFC we
questioned whether the increase in mPFC HA efﬂux observed
after treatment with antipsychotic drugs is linked to antag-
onism of histamine H1 receptors. To test this hypothesis,
we evaluated the ability of the potential novel antipsychotic
FMPD [6-ﬂuoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-
yl]-2-methyl-4H -3-thia-4,9-diaza-benzo[f]azulene] to modulate
histamine efﬂux in the mPFC. FMPD was chosen since it has
high afﬁnity for dopamine D2 (Ki 6.3 nM), 5-HT2A (Ki 7.3 nM),
and 5-HT6 (Ki 8.0 nM) human recombinant receptors but has
lower afﬁnity for histamine H1 (Ki 30 nM) and 5-HT2C (Ki
102 nM) human recombinant receptors than olanzapine (Ras-
mussen et al., 2005). A two-way ANOVA on the FMPD data
indicated a signiﬁcant effect of drug [F(3, 190)= 4.532; P < 0.01]
and time [F(9, 190)= 8.78; P < 0.001] but no drug× time inter-
action. However, Bonferroni post hoc comparisons and analysis
of the average percent of baseline over 3.5 h post-injection of
drug FMPD [1–10 mg/kg; F(3, 22)= 1.628; NS] did not reveal
any signiﬁcant differences between FMPD and the vehicle control
group.
EFFECT OF CLOZAPINE OR PYRILAMINE ON HA EFFLUX AFTER LOCAL
PERFUSION INTO THE mPFC
The local perfusion of either clozapine (1–300 μM) or pyril-
amine (1–300 μM) failed to affect histamine efﬂux in the mPFC
(Figure 5).
RELATIONSHIP BETWEEN AFFINITIES FOR RECEPTOR SUBTYPES AND
THE ABILITY TO INCREASE EXTRACELLULAR HA LEVELS IN THE mPFC
In order to further evaluate the individual contribution of receptor
subtypes, we examined the relationship between the propensity
of the 9 antipsychotic drugs tested to increase extracellular his-
tamine and their afﬁnities at 11 receptors. Of the 11 receptors
examined, only the correlations between mPFC HA efﬂux and Ki
for histamine H1 receptors (r2 = 0.649; n = 16; P < 0.0001) and
5-HT6 receptors (r2 = 0.629; n = 16; P < 0.0001; see Figure 6)
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FIGURE 5 |The effect of pyrilamine or clozapine on HA efflux after local
perfusion into mPFC. Data are mean±SEM of the dialyzate HA levels,
expressed as a percentage of the baseline. n =5–6 rats per group.
were statistically signiﬁcant. However, the correlation with 5-HT6
receptors appears to be co-incidental since the 5-H6 receptors spe-
ciﬁc compound Ro 46-6760 did not increase HA. There was no
correlation with the Ki values for 5-HT2A receptors (r2 = 0.0469;
n = 17; NS) or other receptor subtypes (D2, 5-HT1A, 5-HT2C,
5-HT7, α1A, α2A, α2B, and α2C, H2, or H3; Table 3).
DISCUSSION
The present study was undertaken to investigate the effects of
atypical antipsychotic drugs on histamine release in the mPFC
and to determine the role of individual monoamine receptor
subtypes in mediating these effects. The major ﬁndings of the
present study are: (1) clozapine olanzapine,quetiapine (20 mg/kg),
perphenazine (3 mg/kg), and chlorpromazine (10 mg/kg) signiﬁ-
cantly increased mPFC histamine efﬂux (2) selective antagonism
of H1 and H3 receptors but not 5-HT2A, 5-HT2C, or 5-HT6 recep-
tors markedly increased histamine efﬂux in the mPFC; (3) the
potential novel antipsychotic drug FMPD, which has a similar
binding proﬁle to that of olanzapine but with lower afﬁnity for H1
receptors, does not increase histamine efﬂux in the mPFC (4) for
the nine antipsychotic drugs examined, afﬁnity at histamine H1
receptors was signiﬁcantly correlated with histamine efﬂux in the
mPFC, whereas afﬁnity at most other monoaminergic receptors
examined, including 5-HT2A, were not.
Atypical antipsychotics drugs, but not typical antipsychotics,
have previously been reported to enhance histaminergic activ-
ity in brain regions including the mPFC and striatum, with the
differences in the ability to modulate histamine efﬂux attributed
to the greater ability of atypical antipsychotic drugs to antago-
nize 5-HT2A receptors. Morisset et al. (1999) hypothesized that in
blocking 5-HT2A receptors, atypical antipsychotics relieves his-
taminergic neurons from tonic serotonergic inhibition. In the
present study we observed signiﬁcant increases in histamine efﬂux
following the administration of olanzapine, clozapine, chlorpro-
mazine, and perphenazine. While all of the antipsychotic drugs
which increased mPFC histamine release in this study possess
antagonist activity at 5-HT2A receptors, it is unlikely that antag-
onism of 5-HT2A receptors accounts for the observed differences
in the ability to modulate histamine efﬂux. Firstly, we failed to
observe a signiﬁcant stimulation of histamine efﬂux in the mPFC
following the administration of the highly selective 5-HT2A recep-
tor antagonistMDL100,907 althoughwedidobserve an effectwith
ketanserin which is discussed in a later section. Secondly, we did
not observe a signiﬁcant correlation between afﬁnity at 5-HT2A
receptors and mPFC histamine efﬂux for the nine antipsychotic
drugs tested. Thirdly, serotonergic inhibition of histamine release
has not been described elsewhere in the literature and previous
in vivo microdialysis (Laitinen et al., 1995) and electrophysiology
studies (Eriksson et al., 2001) suggest that endogenous 5-HT has
a stimulatory not inhibitory effect on histaminergic neurons. For
example, 5-HT is known to inhibit the ﬁring of GABA containing
ventrolateral preoptic neurons (VPLO) which are primarily acti-
vated during sleep and play an important role in the silencing his-
taminergic neurons. Thus by inhibiting VPLO neurons, serotonin
may stimulate histamine release by freeing histaminergic neurons
from GABAergic inhibition. Together, these ﬁndings argue against
a signiﬁcant role for 5-HT2A receptors in the differential effects of
antipsychotics on histamine efﬂux.
Our data suggest that the differences in the ability of the
antipsychotics to modulate histamine efﬂux are unlikely to be
accounted for by interactions with D2 receptors as all of the
antipsychotic drugs tested block D2 receptors (although some
with lower potency, e.g., clozapine and quetiapine). Antagonism
of histamine H3 receptors is also unlikely to underlie the increased
histaminergic activity following antipsychotic drugs. Although the
selective H3 receptor antagonist ciproxifan signiﬁcantly increased
histamine efﬂux in the mPFC, we observed increases in histamine
efﬂux following the treatment with several antipsychotic drugs
(clozapine, olanzapine, chlorpromazine, perphenazine, and que-
tiapine) but only clozapine and olanzapine are known to have
antagonistic effects at H3 receptors. Furthermore, clozapine and
olanzapine (708 nM; and >1 μM respectively; Bymaster et al.,
1999) have very low afﬁnity atH3 receptors yet they increasemPFC
histamine levels to a degree comparable with ciproxifan which has
nM afﬁnity for H3 receptors. Thus differences in the degree of
antagonism of dopamine D2 receptors or H3 receptors by antipsy-
chotic drugs do not appear to account for the observed histamine
response to antipsychotic drugs.
In this study we observed a signiﬁcant increase in hista-
mine efﬂux following the administration of 5-HT2A antagonist
ketanserin, which is in agreement with the increase in brain t-
MeHA levels in mice reported by Morisset et al. (1999). However,
in light of failure of the more selective 5-HT2A receptor antagonist
MDL 100,907 to increase histamine efﬂux in the mPFC and the
lackof correlationbetween5-HT2A receptor afﬁnity andhistamine
efﬂux for the antipsychotic drugs tested, it seems likely that the
ability of ketanserin to increase histaminergic activity is mediated
by an interaction at another receptor subtype. Indeed, ketanserin
is known to have afﬁnities at receptors other than 5-HT2A recep-
tors including 5-HT2C (Wainscott et al., 1996), α1 adrenoceptors
(Bøgesø et al., 1988), and histamine H1 receptors (Ghoneim et al.,
2006). Moreover, ketanserin’s afﬁnity for histamine H1 receptors is
comparable to that of its afﬁnity at 5-HT2A receptors (1.8 and2 nM
Frontiers in Psychiatry | Schizophrenia May 2012 | Volume 3 | Article 49 | 8
Fell et al. Antipsychotic drugs and histamine efﬂux
Ve
hic
le 
s.c
.
Ve
hic
le 
p.o
.
Ol
an
za
pin
e 1
0 m
g/k
g
Cl
oz
ap
ine
 10
 m
g/k
g
Pe
rp
he
na
zin
e 3
 m
g/k
g
Ch
lor
pr
om
az
ine
 10
 m
g/k
g
Qu
eti
ap
ine
 10
 m
g/k
g
Ri
sp
eri
do
ne
 1 
mg
/kg
FM
PD
 10
 m
g/k
g
Ha
lop
eri
do
l 0
.5 
mg
/kg
Ar
ipi
pr
az
ole
 10
 m
g/k
g
0
50
100
150
200
250
300
3.
5 
H
ou
r A
ve
ra
ge
 (%
 H
A
)
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
1.4
1.5
1.6
1.7
1.8
1.9
2.0
2.1
2.2
2.3
2.4
2.5
2.6
2.7
r2 = 0.539 n=17;  P<0.001
Olanz
Perph Cloz
Chlorp
Quet
Risp
FMPD
HalopArip
Pyril
Log [Ki H1 receptor]
Lo
g 
[%
 H
A
 R
el
ea
se
]
A
B
FIGURE 6 | Effects of typical and atypical antipsychotic drugs or
vehicle on histamine efflux in the mPFC. Summary data in (A)
represents the mean average percent of baseline HA (±SEM) for the
3.5 h post-drug or vehicle. Data in (B) shows the correlation between
propensity of nine antipsychotic drugs to induce histamine efﬂux (log
%HA) in the mPFC and afﬁnity (log Ki) at histamine H1 receptors. Log
3.5 h average %HA values were plotted against the afﬁnity (log Ki) at
human receptors and where data existed against afﬁnity (log Ki) at rat
receptors. All Ki values used are shown in Tables S1 and S2 in
Supplementary Material.
respectively; Wainscott et al., 1996; Ghoneim et al., 2006). Thus at
doses at which ketanserin occupies 5-HT2A receptors, signiﬁcant
occupancy at histamine H1 receptors would also be expected. It
should be noted that MDL 100,907 also has afﬁnity for the hist-
amine H1 receptor but this is considerably lower than its afﬁnity
for 5-HT2A receptors (66.7 vs 0.84 nM; Pehek et al., 2006).
The interaction with histamine H1 receptors by ketanserin is of
particularly relevance considering that we observed a signiﬁcant
increase in histamine efﬂux following the administration of three
histamine H1 receptor antagonists (pyrilamine, triprolidine, and
diphenhydramine). When administered acutely, the histamine H1
receptor antagonist pyrilamine enhanced histamine efﬂux in a
dose dependent fashion and reached a maximal increase in the
mPFCcomparable to the histamineH3 receptor antagonist ciprox-
ifan. Furthermore, increases in mPFC histamine efﬂux were also
observed after treatment with additional histamine H1 receptor
www.frontiersin.org May 2012 | Volume 3 | Article 49 | 9
Fell et al. Antipsychotic drugs and histamine efﬂux
Table 3 | Correlation between propensity of 9 antipsychotic drugs to
induce histamine efflux (log %HA) in the mPFC and affinity (log K i )
for 13 receptors.
Receptor r2 n P -value
D2 0.166 17 NS
H1 0.539 17 <0.001
H2 0.218 6 NS
H3 0.127 6 NS
α1A 0.037 9 NS
α2A 0.001 9 NS
α2B 0.337 9 NS
α2C 0.176 9 NS
5-HT1A 0.126 15 NS
5-HT2A 0.017 17 NS
5-HT2C 0.158 15 NS
5-HT6 0.618 18 <0.001
5-HT7 0.006 15 NS
Log HA% of baseline (3.5 h Average) values were plotted against the afﬁnity
(log Ki) at human receptors and where data existed against afﬁnity (log Ki) at rat
receptors. All Ki values used are shown in Tables S1 and S2 in Supplementary
Material.
antagonists including diphenhydramine and triprolidine. To our
knowledge, a stimulatory effect of histamine H1 receptor antag-
onists on histamine efﬂux has not been previously shown and
the mechanism by which antagonism of histamine H1 recep-
tors leads to enhanced histaminergic neuron activity is currently
unknown. Nevertheless, all the antipsychotic drugs examined
which increased histamine efﬂux have high afﬁnity (<15 nM) at
the histamine H1 receptor. When we examined the relationship
between afﬁnity at histamine H1 receptors and mPFC histamine
efﬂux we found a highly signiﬁcant correlation which suggests that
antagonism of histamine H1 receptors may mediate the increase in
histaminergic neuronal activity following antipsychotic treatment.
It should be noted that we also observed a signiﬁcant correlation
between 5-HT6 receptor afﬁnity and histamine efﬂux but this
interaction seems unlikely to mediate the effect of antipsychotic
drugs on histamine efﬂux as administration of the selective 5-HT6
antagonist Ro 04-6790 failed to increase histamine efﬂux. In this
study we also demonstrated that the potential novel antipsychotic
FMPD which also has high afﬁnity for 5-HT6 receptors, has no
effect on histamine efﬂux in the mPFC. Importantly, FMPD has a
binding proﬁle similar to that of olanzapine but with lower afﬁn-
ity for histamine H1 receptors (Rasmussen et al., 2005). In general
FMPD produces pharmacological effects over a similar dose range
to that of olanzapine (Rasmussen et al., 2005), thus FMPD’s fail-
ure to increase histamine efﬂux over the dose range 1–10 mg/kg is
unlikely to be due to insufﬁcient target receptor occupancy. Simi-
larly, other antipsychotic drugs with lower afﬁnity at H1 receptors
such as haloperidol, risperidone, and aripiprazole also failed to sig-
niﬁcantly enhance histamine efﬂux. Together, these ﬁndings sug-
gest that the effects of antipsychotic drugs on histamine neuronal
activity may be attributable to antagonism of histamine H1 recep-
tors. The location of the histamine H1 receptors, whose blockade
mediates the increase in cortical histamine efﬂux, is unknown. In
contrast to their effects after systemic administration, the local per-
fusion of clozapine or pyrilamine into the mPFC failed to enhance
histamine efﬂux within the mPFC suggesting that the PFC is not
the site of action. Preliminary unpublished observations from our
laboratory indicate that perfusion of pyrilamine into the TMN
does cause a release of histamine in the PFC but more work is
needed to conﬁrm this conclusion.
In summary, by using in vivo microdialysis we have demon-
strated that the acute administration of olanzapine, clozapine,
quetiapine as well as chlorpromazine and perphenazine increase
histamine efﬂux in the mPFC. The magnitude of histamine efﬂux
observed following the administration of perphenazine or chlor-
promazine was comparable to that of atypical antipsychotic drugs
such as clozapine or olanzapine. These data therefore suggest
that enhanced histaminergic activity is not an exclusive property
of atypical antipsychotic drugs. Furthermore, our data suggest
that the ability of these drugs to increase histaminergic neuronal
activity may be related to their ability to antagonize histamine
H1 receptors and is not attributable to antagonism of 5-HT2A
receptors. The mechanism by which the blockade of histamine
H1 receptors leads to increased histamine efﬂux is unknown and
warrants further investigation.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at http://www.frontiersin.org/Schizophrenia/10.3389/fpsyt.2012.
00049/abstract
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